2024 Revenues ($USD) : $2.87B
Shionogi continues to advance its infectious disease portfolio with recent announcements including positive Phase 2 results for their RSV oral antiviral candidate S-337395 in January 2025. The company has made strategic moves including the acquisition of Qpex Biopharma for approximately $140 million in 2023, while undergoing organizational changes with the upcoming absorption of UMN Pharma's vaccine production function into Shionogi Pharma effective April 2025. Shionogi remains optimistic about potential future revenue from its COVID-19 pill Xocova following approvals in Japan, with expectations of reaching $2 billion in annual sales once U.S. approval is secured.